Drug General Information (ID: DDI9YA2BFX)
Drug Name			Asparaginase Escherichia coli		Drug Info		Caplacizumab		Drug Info
Drug Type		Protein/peptide				Monoclonal antibody
Therapeutic Class		Antineoplastics				Platelet Aggregation Inhibitors

Mechanism of Asparaginase Escherichia coli-Caplacizumab Interaction (Severity Level: Moderate)
Increased risk of bleeding Click to Show/Hide Mechanism Graph
Drug Name		Asparaginase Escherichia coli				Caplacizumab
Mechanism		Risk of bleeding Anticoagulant effects				Risk of bleeding Antiplatelet
Key Mechanism Factor 1
		Factor Name		Bleeding
		Factor Description		Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc.
Mechanism Description		Increased risk of bleeding by the combination of Asparaginase Escherichia coli and Caplacizumab

Recommended Action
Management		Coagulation parameters should be monitored at baseline and periodically during concomitant treatment with asparaginase and anticoagulants such as heparin, dipyridamole, aspirin and nonsteroidal anti-inflammatory drugs. Patients should be advised to promptly report any signs and symptoms of bleeding.

References
1	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Duarte X, Esteves S, Neto AM, Pereira F "Incidence and risk factors for central nervous system thrombosis in paediatric acute lymphoblastic leukaemia during intensive asparaginase treatment: a single-centre study." Br J Haematol 174 (2016): 280-91. [PMID: 27018199]